Sitap 100 mg (Tablet)
Unit Price: ৳ 28.08 (1 x 10: ৳ 280.80)
Strip Price: ৳ 280.80
Medicine Details
| Category | Details |
|---|---|
| Generic | Sitagliptin |
| Company | Aci limited |
| Also available as |
Indications
- Adjunct to diet and exercise for type 2 diabetes mellitus
- Not to be used in patients with type 1 diabetes
- Not to be used for the treatment of diabetic ketoacidosis
- Not studied in patients with a history of pancreatitis
Pharmacology
- DPP-4 inhibitor
- Increases and prolongs action of incretin hormones
- Involvement in physiologic regulation of glucose homeostasis
- Increases insulin release and decreases glucagon levels in a glucose-dependent manner
Dosage & Administration
- Recommended dose of 50 mg twice a day or 100 mg once daily
- Can be taken with or without food
Interaction
- Did not meaningfully alter the pharmacokinetics of various drugs
- Slightly increases the mean concentration of Digoxin
Contraindications
- History of serious hypersensitivity reaction to sitagliptin
Side Effects
- Common adverse reactions include headache, upper respiratory tract infection, and nasopharyngitis
- Hypoglycemia may occur in patients treated with the combination of Sitap and sulfonylurea, and add on to insulin
Pregnancy & Lactation
- Pregnancy Category B
- Should be used during pregnancy only if clearly needed
- Caution should be exercised when administered to a nursing woman
Precautions & Warnings
- Prompt discontinuation if pancreatitis is suspected
- Dosage adjustment recommended in patients with renal insufficiency
- Dosage adjustment required when used in combination therapy with medications known to cause hypoglycemia
- Post-marketing reports of serious hypersensitivity reactions
- Safety and effectiveness in pediatric patients under 18 years of age not established
Use in Special Populations
- Substantially excreted by the kidney
- Dose selection should be taken with care in the elderly
- No dosage adjustment required for patients with mild renal insufficiency
- Dose of 50 mg once daily for patients with moderate renal insufficiency
- Dose of 25 mg once daily for patients with severe renal insufficiency or end-stage renal disease
Overdose Effects
- Maximal mean increase in QTc observed at high doses
- No dose-related clinical adverse reactions observed with doses up to 600 mg per day
- Modestly dialyzable, approximately 13.5% of the dose removed over a 3- to 4-hour hemodialysis session
Therapeutic Class
- Dipeptidyl Peptidase-4 (DPP-4) inhibitor
Storage Conditions
- Store below 25°C in a dry place away from light
- Keep out of the reach of children
- Do not use later than the date of expiry
- To be dispensed only on the prescription of a registered physician